Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.52 |
| ▸ | MOGAT2 | Q3SYC2 | 5/20 | 0.49 |
| ▸ | MGAT2 | Q10469 | 5/20 | 0.49 |
| ▸ | PRKDC | P78527 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | MGAT1 | P26572 | 1/20 | 0.40 |
| ▸ | MGAT3 | Q09327 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5403860 | 0.91 | AR (0.50) | ARMOGAT2MGAT2PRKDCMGAT1 | |
| SCHEMBL5377229 | 0.88 | AR (0.47) | ARMOGAT2MGAT2PRKDCLRRK2 | |
| SCHEMBL7139382 | 0.88 | AR (0.64) | ARMOGAT2MGAT2MEN1KMT2A | |
| SCHEMBL5369240 | 0.88 | LRRK2 (0.57) | MOGAT2MGAT2PRKDCLRRK2MGAT1 | |
| SCHEMBL5358718 | 0.87 | ERBB2 (0.49) | ARMOGAT2MGAT2PRKDCLRRK2 | |
| SCHEMBL5376628 | 0.87 | AR (0.47) | ARMOGAT2MGAT2PRKDCMGAT1 | |
| SCHEMBL7136795 | 0.86 | AR (0.57) | ARMOGAT2MGAT2PRKDCMEN1 | |
| SCHEMBL5368362 | 0.85 | SRC (0.49) | LRRK2AURKA | |
| SCHEMBL5361276 | 0.85 | AR (0.49) | ARMOGAT2MGAT2PRKDCMEN1 | |
| SCHEMBL5357745 | 0.85 | MOGAT2 (0.58) | ARMOGAT2MGAT2PRKDCLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | FRK, PTK2, DSTYK | AR 1805/4885MOGAT2 1159/4885MGAT2 4714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.